Kura Oncology Announces up to $300 Million Strategic Financing Agreement

Chicago – November 10, 2026 – Cooley advised Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for cancer, on its up to $300 million strategic debt, equity and royalty financing agreements with affiliates of Oberland Capital. The financing includes up to $275 million in debt financing and $25 million in equity investments, subject to applicable conditions.  The financing also provides for a single-digit royalty tied to U.S. KOMZIFTI net sales, capped at 20% of the aggregate principal amount of term loans advanced under the agreement.

Lawyers Addison Pierce and Charles Watkins led the interdisciplinary Cooley team advising Kura. The team also included Charity Williams, Chen Chen and Jonathan Kaufman from the life sciences partnering practice group, Jon Brose and Amanda Pacheco from the tax practice group and Wade Andrews from the emerging companies and venture capital practice group.

Cooley has represented Kura Oncology since its inception in 2014, guiding the company through its initial funding, initial public offering and follow-on offerings, including its oversubscribed $150 million private placement in January 2024, as well as its global strategic collaboration with Kyowa Kirin in November 2024.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.